Latest1 information on COVID-19
©2022 Stanford Medicine
Trial ID: NCT01127061
A Randomized Trial of Moderate Intensity Exercise Training in Hypertrophic Cardiomyopathy
Associate Dean, School of Medicine, Roger and Joelle Burnell Professor of Genomics and Precision Health, Professor of Medicine (Cardiovascular Medicine), of Genetics, of Biomedical Data Science and, by courtesy, of Pathology
- Age ≥ 18 years and ≤ 80.
- Diagnosis of HCM, defined by the presence of unexplained left-ventricular hypertrophy
> 13 mm in any wall segment.
- Agreement to be a participant in the study protocol and willing/able to return for
- History of exercise-induced syncope or arrhythmias (ventricular tachycardia or
non-sustained ventricular tachycardia).
- Medically refractory left ventricular outflow tract obstruction being evaluated for
septal reduction therapy.
- Less than 3 months post septal reduction therapy (surgery or catheter based
- Hypotensive response to exercise (> 20 mm Hg drop in systolic blood pressure from peak
blood pressure to post exercise blood pressure).
- Implantable Cardioverter-Defibrillator (ICD) placement in last 3 months or scheduled.
- Left ventricular systolic dysfunction (left ventricular ejection fraction < 55% by
- Worsening clinical status in the last 3 months, advanced heart failure (New York Heart
Association class IV symptoms) or angina (Canadian Cardiovascular Society class IV
- Life expectancy less than 12 months.
- Inability to exercise due to orthopedic or other non-cardiovascular limitations.
- Unwillingness to refrain from competitive sports, burst activity, or heavy isometric
exercise for the duration of the study.
behavioral: Exercise training
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Heidi Salisbury, BS, RN, MSN